Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
Executive Summary
Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.
You may also be interested in...
Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising
Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.
Biopharma Quarterly Dealmaking Statistics, Q2 2018
Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.
Start-Up Quarterly Statistics: A Record-Breaking Q2 As Financings Surge
Biopharma start-ups had a record-breading quarter in terms of fundraising. A review of biopharma start-up deal-making and financing activity from April through June 2018, based on data from Strategic Transactions.